ARTICLE | Company News
Kyowa Hakko Kirin, sanofi-aventis deal
May 18, 2009 7:00 AM UTC
Kyowa granted sanofi-aventis exclusive, worldwide rights to develop a human mAb against tumor necrosis factor ligand superfamily member 14 ( TNFSF14, LIGHT, CD258), except in Asia where the companie...